Novo lays off 400 in R&D unit

Sep 18, 2018

Novo Nordisk have announced that it will lay off 400 employees China and Denmark. The decision was made in order to invest in biological and technological innovation.

According to the diabetes drugmaker, this is not meant to be a cost-cutting measure and in fact, its R&D budget will be even larger next year. Novo’s chief science officer Mads Krogsgaard Thomsen also said that it had  a surplus of manual labor but were lagging in the digital sphere, informatics, data science, artificial intelligence and automation.

The company will increase investment in innovation in core therapy areas and beyond.

Read the Reuters report

Want to get news like this in your inbox?  Subscribe to our eNewsletter here!

Show Comments
Hide Comments

Join the discussion

We welcome your thoughtful comments.
All comments will display your user name.

Want to participate in the discussion?

Register for free

Log in for complete access.


No one has commented on this page yet.

RSS feed for comments on this page | RSS feed for all comments